Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.

Aribi A, Borthakur G, Ravandi F, Shan J, Davisson J, Cortes J, Kantarjian H.

Cancer. 2007 Feb 15;109(4):713-7.

2.

Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review.

Thorpe M, Montalv√£o A, Pierdomenico F, Moita F, Almeida A.

Leuk Res. 2012 Aug;36(8):1071-3. doi: 10.1016/j.leukres.2012.04.024. Epub 2012 May 17. Review.

PMID:
22607959
3.

Decitabine and its role in the treatment of hematopoietic malignancies.

Plimack ER, Kantarjian HM, Issa JP.

Leuk Lymphoma. 2007 Aug;48(8):1472-81. Review.

PMID:
17701577
4.

Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.

Parikh SA, Tefferi A.

Am J Hematol. 2013 Nov;88(11):967-74. doi: 10.1002/ajh.23574. Review.

5.

Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.

Parikh SA, Tefferi A.

Am J Hematol. 2012 Jun;87(6):610-9. doi: 10.1002/ajh.23203. Review.

6.

Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.

Xie M, Jiang Q, Xie Y.

Clin Lymphoma Myeloma Leuk. 2015 Jan;15(1):22-8. doi: 10.1016/j.clml.2014.04.010. Epub 2014 Jun 12. Review.

PMID:
25042977
7.

Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.

Silverman LR, Mufti GJ.

Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S12-23. Review.

PMID:
16341236
8.

5-azacytidine and decitabine monotherapies of myelodysplastic disorders.

Kuykendall JR.

Ann Pharmacother. 2005 Oct;39(10):1700-9. Epub 2005 Sep 6. Review.

PMID:
16144884
9.

Inhibitors of DNA methylation: beyond myelodysplastic syndromes.

Fenaux P.

Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S36-44. Review.

PMID:
16341239
10.

The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.

Merkel DG, Nagler A.

Expert Rev Hematol. 2013 Dec;6(6):665-76. doi: 10.1586/17474086.2013.854699. Epub 2013 Nov 6. Review.

PMID:
24191866
11.

The use of hypomethylating agents in the treatment of hematologic malignancies.

Kihslinger JE, Godley LA.

Leuk Lymphoma. 2007 Sep;48(9):1676-95. Review.

PMID:
17786703
12.

[Decitabine for treatment of myelodysplastic syndrome in an elderly patient and review of literature].

Gao Y, Ping B, Zhou S.

Nan Fang Yi Ke Da Xue Xue Bao. 2012 Feb;32(2):280-2. Review. Chinese.

13.

DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.

Griffiths EA, Gore SD.

Semin Hematol. 2008 Jan;45(1):23-30. doi: 10.1053/j.seminhematol.2007.11.007. Review.

14.

Current management of patients with chronic myelomonocytic leukemia.

Alfonso A, Montalban-Bravo G, Garcia-Manero G.

Curr Opin Oncol. 2017 Jan;29(1):79-87. Review.

PMID:
27849645
15.

Decitabine. MGI Pharma Inc/SuperGen Inc.

Arthur C.

IDrugs. 2004 Dec;7(12):1113-32. Review.

PMID:
15599805
16.

Immune thrombocytopenia in chronic myelomonocytic leukemia.

Hadjadj J, Michel M, Chauveheid MP, Godeau B, Papo T, Sacre K.

Eur J Haematol. 2014 Dec;93(6):521-6. doi: 10.1111/ejh.12393. Epub 2014 Jun 28. Review.

PMID:
24913055
17.

Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies.

Lyons J, Bayar E, Fine G, McCullar M, Rolens R, Rubinfeld J, Rosenfeld C.

Curr Opin Investig Drugs. 2003 Dec;4(12):1442-50. Review.

PMID:
14763130
18.

Decitabine.

Issa JP.

Curr Opin Oncol. 2003 Nov;15(6):446-51. Review.

PMID:
14624227
19.

How I treat chronic myelomonocytic leukemia.

Solary E, Itzykson R.

Blood. 2017 Jul 13;130(2):126-136. doi: 10.1182/blood-2017-04-736421. Epub 2017 Jun 1. Review.

PMID:
28572287
20.

The clinical management of chronic myelomonocytic leukemia.

Padron E, Komrokji R, List AF.

Clin Adv Hematol Oncol. 2014 Mar;12(3):172-8. Review.

PMID:
24927265

Supplemental Content

Support Center